Divi’s Laboratories has dipped 6% to Rs 1,030 after reporting 17% year-on-year (yoy) decline in its consolidated net profit at Rs 181 crore for the fourth quarter ended March 31, 2013 , due to foreign exchange loss during the period.
The pharmaceutical company had posted a net profit of Rs 217 crore in the same period of previous fiscal.
“Net sales too, declined 9% to Rs 656 crore on yoy basis,” Divi’s Laboratories said in a statement.
Analyst on an average had expected net profit of Rs 216 crore and net sales of Rs 803 crore for the quarter.
Meanwhile, the board has recommended a dividend of 750% or Rs 15 per share of Rs 2 each for the year ended March 31, 2013.
The stock opened at Rs 1,062 and hit a low of Rs 1,016 on NSE. A combined 198,226 shares changed hands on the counter so far on NSE and BSE.
The pharmaceutical company had posted a net profit of Rs 217 crore in the same period of previous fiscal.
“Net sales too, declined 9% to Rs 656 crore on yoy basis,” Divi’s Laboratories said in a statement.
Analyst on an average had expected net profit of Rs 216 crore and net sales of Rs 803 crore for the quarter.
Meanwhile, the board has recommended a dividend of 750% or Rs 15 per share of Rs 2 each for the year ended March 31, 2013.
The stock opened at Rs 1,062 and hit a low of Rs 1,016 on NSE. A combined 198,226 shares changed hands on the counter so far on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%